1. Ziebart, T., Pabst, A., Klein, M.O., Kammerer, P., Gauss, L., Brullmann, D., Al-Nawas, B., and Walter, C. (2011). Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15, 105-111.
2. Gao, S.Y., Zheng, G.S., Wang, L., Liang, Y.J., Zhang, S.E., Lao, X.M., Li, K., and Liao, G.Q. (2017). Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS One 12, e0179248.
3. Manfredi, M., Mergoni, G., Goldoni, M., Salvagni, S., Merigo, E., Meleti, M., and Vescovi, P. (2017). A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors. Med Oral Patol Oral Cir Bucal 22, e342-e348.
4. Soares, M.Q.S., Van Dessel, J., Jacobs, R., Da Silva Santos, P.S., Cestari, T.M., Garlet, G.P., Duarte, M.a.H., Imada, T.S.N., Lambrichts, I., and Rubira-Bullen, I.R.F. (2018). Zoledronic Acid Induces Site-Specific Structural Changes and Decreases Vascular Area in the Alveolar Bone. J Oral Maxillofac Surg 76, 1893-1901.
5. Anagnostis, P., Paschou, S.A., Mintziori, G., Ceausu, I., Depypere, H., Lambrinoudaki, I., Mueck, A., Perez-Lopez, F.R., Rees, M., Senturk, L.M., Simoncini, T., Stevenson, J.C., Stute, P., Tremollieres, F.A., and Goulis, D.G. (2017). Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101, 23-30.
6. Adams, A.L., Adams, J.L., Raebel, M.A., Tang, B.T., Kuntz, J.L., Vijayadeva, V., Mcglynn, E.A., and Gozansky, W.S. (2018). Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Miner Res 33, 1252-1259.
7. Bindon, B., Adams, W., Balasubramanian, N., Sandhu, J., and Camacho, P. (2018). Osteoporotic Fractures during Bisphosphonate Drug Holiday. Endocr Pract 24, 163-169.
8. Malan, J., Ettinger, K., Naumann, E., and Beirne, O.R. (2012). The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 114, 671-676.
9. Higuchi, T., Soga, Y., Muro, M., Kajizono, M., Kitamura, Y., Sendo, T., and Sasaki, A. (2018). Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125, 547-551.
10. Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., Garcia-Sanz, R., Durie, B., Legiec, W., Krejci, M., Laribi, K., Zhu, L., Cheng, P., Warner, D., and Roodman, G.D. (2018). Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19, 370-381.
11. Bedogni, A., Campisi, G., Fusco, V., and Agrillo, A. (2013). Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione. Cleup Ed.
12. Campisi, G., Fedele, S., Fusco, V., Pizzo, G., Di Fede, O., and Bedogni, A. (2014). Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 10, 257-275.